The company has not filed an annual or quarterly report since its Q2 FY2020 10-Q, filed Aug 10, 2020. Its latest SEC filing is a SC 13G/A from Nov 10, 2020.
10-Q for Q2 FY2020, filed Aug 10, 2020
The sections below describe the company as of the FY2019 annual report.
Develops biologic drug candidates for people with rare immune-mediated diseases and has generic medicines and a biosimilar candidate for other conditions.
10-K for FY2019, filed Feb 27, 2020We are a biotechnology company focused on the discovery and development of novel biologic therapies for the treatment of rare…View ↗
While we have terminated all future development of any new or early stage biosimilar and complex generic products, we have retained our…View ↗
In October 2018, we announced and later completed a restructuring of our business in order to focus the majority of our resources on our…View ↗
M710—Biosimilar EYLEA® (aflibercept) CandidateView ↗
Pharmaceutical partners may pay upfront for a license and for research work; later payments can depend on development goals or sales of licensed products, including royalties or profit shares.
10-K for FY2019, filed Feb 27, 2020
$23.9M
10-K for FY2019, filed Feb 27, 2020
$23.9M ↗
Sandoz markets GLATOPA; Mylan would market the EYLEA biosimilar if approved, and CSL is responsible for marketing its licensed M230 product.
10-K for FY2019, filed Feb 27, 2020GLATOPA 20 mg/mL was approved by the FDA in April 2015 and was launched in June 2015. GLATOPA 20 mg/mL, the first "AP" rated, substitutable…View ↗
M710 is being developed in collaboration with Mylan. Under our collaboration agreement, we and Mylan share equally costs and profits…View ↗
Pursuant to the License and Option Agreement, effective February 17, 2017, with CSL Behring Recombinant Facility AG, or CSL, a wholly-owned…View ↗
8-K, filed Oct 1, 2020
Following completion of the Offer, on October 1, 2020, Merger Sub merged with and into the Company pursuant to Section 251(h) of the…View ↗
8-K, filed Aug 19, 2020
Johnson & Johnson to acquire Momenta for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to…View ↗
Shrank. Revenue fell 73% in 4 years, from $89.7M in to $23.9M in , about 28% a year.
Strategic focus
The older report described work across complex generics, biosimilars and novel therapeutics; the latest centers on biologic candidates for rare immune-mediated diseases, while retaining selected commercial generics and a biosimilar program.
10-K for FY2016, filed Feb 24, 2017 10-K for FY2019, filed Feb 27, 2020We are a biotechnology company focused on the discovery and development of novel biologic therapies for the treatment of rare…View ↗
While we have terminated all future development of any new or early stage biosimilar and complex generic products, we have retained our…View ↗
In October 2018, we announced and later completed a restructuring of our business in order to focus the majority of our resources on our…View ↗
Competes with UCB, Argenx, Alexion, Immunovant, Ra Pharmaceuticals, Rigel Pharmaceuticals, Octapharma, Shire, CSL Behring, Grifols, Principia, Protalex, Pfizer, Coherus, Formycon, Alteogen, Insight Biopharmaceuticals, Lupin, Teva, and Mylan
10-K for FY2019, filed Feb 27, 2020Several companies are developing FcRn targeted agents. UCB has initiated a Phase 3 clinical study in immune thrombocytopenic purpura, or…View ↗
Loading...
